Akathisia Can Develop Within Days of Starting Invega Sustenna
Akathisia can occur very rapidly after initiating Invega Sustenna, potentially appearing within the first week after the initial loading doses. According to the FDA label, akathisia was reported in clinical trials during the acute treatment phase, with incidence rates of 3-6% across different dose groups in the first 9-13 weeks 1. The drug's pharmacokinetic profile shows therapeutic plasma levels are achieved quickly with the loading dose regimen (234 mg deltoid on day 1, followed by 156 mg on day 8), reaching average concentrations of 34.7 ng/mL after just the second injection 2.
Timeline and Risk Factors
The two-injection loading strategy (days 1 and 8) is specifically designed to rapidly achieve therapeutic drug levels, which means extrapyramidal symptoms including akathisia can manifest within days of the first injection. Research demonstrates that:
- Symptom improvements begin by day 4 in markedly ill patients, indicating rapid drug activity 3
- The deltoid loading doses create immediate therapeutic exposure that persists throughout treatment 2
- Akathisia was among the most common EPS-related adverse events in clinical trials, appearing during the initial treatment period 1
Incidence Data from Clinical Trials
The FDA label provides specific akathisia rates during acute treatment phases 1:
- Placebo: 2%
- 39 mg/4 weeks: 2%
- 78 mg/4 weeks: 2%
- 156 mg/4 weeks: 3%
In real-world studies, akathisia occurred in 11.1% of patients receiving paliperidone palmitate for acute exacerbations 4, and 7.0% in markedly-to-severely ill patients 3. The 234 mg loading dose study showed hyperkinesia (which includes akathisia) rates of 1.3-5.5% depending on maintenance dose 1.
Clinical Monitoring Strategy
Monitor for akathisia starting immediately after the first injection and continuing through the first month. Key assessment points:
- Days 1-7: Watch for early-onset akathisia following the first deltoid injection
- Day 8 and beyond: Reassess after the second loading dose, as cumulative drug exposure increases risk
- Weeks 2-4: Continue vigilant monitoring as steady-state approaches
Use the Barnes Akathisia Rating Scale for objective assessment 1. The FDA label notes that rating scale assessments showed dose-related patterns, with higher incidence at 156 mg doses (11% akathisia by rating scales) compared to 78 mg (5%) and placebo (4%) 1.
Important Caveats
The loading dose regimen carries higher EPS risk than gradual titration. One case report documented severe and prolonged Parkinsonism from the recommended loading strategy 5, emphasizing that not all patients tolerate rapid dose escalation. The 234 mg initiation dosing showed EPS rates of 6-11% depending on maintenance dose, with hyperkinesia being the most frequent category 1.
Younger males face elevated risk for acute dystonia (a related EPS), which can occur within the first few days 1. While akathisia and dystonia are distinct, this highlights that extrapyramidal effects generally emerge early in treatment.
If akathisia develops, consider anticholinergic medications promptly per guideline recommendations to address side effects early 6. The safety profile shows akathisia typically responds to standard interventions, with most cases being manageable without discontinuation 1, 7.